logo BDSP

Base documentaire

  1. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine : Implications for HIV screening.

    Article - En anglais


    - To estimate the economic impact of (1) treating pregnant women who are human immunodeficiency virus (HIV) - positive with zidovudine and (2) voluntary screening programs for pregnant women for HIV infection and offering treatment with zidovudine to those found to be HIV-positive.

    Main Outcome Measures

    - Number of cases of pediatric HIV infection and costs of screening, zidovudine treatment, and pediatric HIV infection treatment.


    - Health care costs associated with treatment of HIV-positive pregnant women and their newboms are estimated as the costs of zidovudine and its administration and the reduction in costs of treating pediatric HIV infection.

    The lifetime costs of pediatric HIV infection are derived from the published literature.

    Estimates of the reduction in maternal-to-fetal transmission rates are taken from the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group (ACTG) Protocol 076.

    Costs of a voluntary screening program include costs of screening tests and counseling.

    Sensitivity and threshold analyses are performed to determine the impact of changes in input parameter values including zidovudine treatment costs, efficacy of treatment, costs of pediatric HIV infection, prevalence of HIV infection in pregnant women, screening test sensitivity and specificity, and pregnancy termination rates on the results.


    - Assuming transmission rates are reduced from 25.5% to 8. (...)

    Mots-clés Pascal : Infection, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Virose, Mère, Gestation, Nouveau né, Homme, Traitement, Coût, Dépistage, Zidovudine, Impact économique, Economie, Adulte, Pyrimidine nucléoside, Antiviral

    Mots-clés Pascal anglais : Infection, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Viral disease, Mother, Pregnancy, Newborn, Human, Treatment, Costs, Medical screening, Economic impact, Economy, Adult, Pyrimidine nucleoside, Antiviral

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0352356

    Code Inist : 002B30A04B. Création : 10/04/1997.